Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 34 min ago
Peer-reviewedCC BY-NC 4.0Cancer

Estimated lifetime harms and benefits of continuing biennial prostate cancer screening in older men by comorbidity group

4 affiliations
  1. 1Division of Public Health Sciences Fred Hutch Cancer Center Seattle Washington USA
  2. 2Department of Biostatistics University of Michigan Ann Arbor Michigan USA
  3. 3Department of Urology University of Washington Seattle Washington USA
  4. 4Division of Geriatrics University of California San Francisco California USA

Abstract

Background: Prostate‐specific antigen (PSA) screening prevents prostate cancer death but also leads to overdiagnosis—diagnosis that would not occur during a man’s lifetime without screening—particularly in older men and those with life‐limiting comorbidities. Modern screening approaches attempt to mitigate overdiagnosis in older men by using a higher PSA threshold for further evaluation using magnetic resonance imaging (MRI), and discontinuing screening in men with low PSA levels. However, long‐term harms and benefits have not been estimated.

Methods: Two microsimulation models estimated lifetime harms and benefits of modern screening approaches in men who were screened biennially at ages 50–70 years, remained undiagnosed with prostate cancer at age 72 years, and faced varying risks of competing mortality based on previously estimated comorbidity‐adjusted life tables.

Results: By using a PSA threshold of 6.5 ng/mL for evaluation with MRI and MRI‐targeted biopsy, estimated ratios of overdiagnoses to cancer deaths prevented were similar when all men aged 70 years or older continued screening versus when only in men with PSA levels ≥ 3.0 ng/mL continued screening. For men with no comorbidities, this ratio increased from 2.7–3.1 at age 72 years to 4.5–5.1 at age 76 years. For men with severe comorbidities, this ratio increased from 9.6–10.2 at ages 72 to 11.3–12.6 at 76 years.

Conclusions: Even using modern approaches, the ratio of overdiagnoses per cancer death prevented increases with age and is at least double in men with severe life‐limiting comorbidities compared with age‐matched men with no comorbidities. The current results can help inform patients and providers about when to stop PSA screening.

Related

  1. Passive early screening for Alzheimer’s disease and related dementias using EHR comorbidity patterns
    Dmytro Onishchenko, James A. Mastrianni, Ishanu Chattopadhyay
    NPJ Digital MedicinePeer-reviewedCC BY-NC-ND 4.0Full textPsychiatry & mental healthPMC
  2. Estimated Small Dense Low-Density Lipoprotein Cholesterol Is Independently Associated With Arterial Stiffness ― Large Japanese Screening Study ―
    Shuya Shinchi, Yuichi Akasaki, Daisuke Tokutake +6
    Circulation JournalPeer-reviewedCC BY-NC-NDFull textCardiovascular medicineJ-STAGE
  3. Associations of perceived benefits, cost burden, and sociodemographic factors with cervical cancer screening by regular physician status among Korean women
    Hye-Sun Lee, Gyeong-U Hong, Hyeon Ji Lee +4
    Scientific ReportsPeer-reviewedCC BYFull textEpidemiology & public healthDOAJ
  4. A supportive intervention on infertile couples for continuing infertility treatments: a randomized trial
    Maryam Ghorbani, Afsaneh Keramat, Masud Yunesian +3
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textObstetrics, gynaecology & paediatricsCrossref
  5. A Comparative Review of Irish and Australian Expert Consensus on Criteria for Initiating and Continuing Reimbursed Janus Kinase Inhibitor Therapy in Alopecia Areata Patients
    Aoife Boyle, John Bourke, Nicola Cooke +15
    Skin Appendage DisordersPeer-reviewedLicence not statedFull textGeneral medicinePMC
BibTeX
@article{gulati2026estimated,
  title = {{Estimated lifetime harms and benefits of continuing biennial prostate cancer screening in older men by comorbidity group}},
  author = {Roman Gulati and Krithika Suresh and Sarah P. Psutka and Jeremy M. G. Taylor and Lukas Owens and Alex Tsodikov and Louise C. Walter and Ruth Etzioni},
  journal = {Cancer},
  year = {2026},
  month = nov,
  doi = {10.1002/cncr.70620},
  url = {https://doi.org/10.1002/cncr.70620},
  note = {CC BY-NC 4.0},
}
RIS
TY  - JOUR
TI  - Estimated lifetime harms and benefits of continuing biennial prostate cancer screening in older men by comorbidity group
AU  - Roman Gulati
AU  - Krithika Suresh
AU  - Sarah P. Psutka
AU  - Jeremy M. G. Taylor
AU  - Lukas Owens
AU  - Alex Tsodikov
AU  - Louise C. Walter
AU  - Ruth Etzioni
PY  - 2026
DA  - 2026/11/12
JO  - Cancer
DO  - 10.1002/cncr.70620
UR  - https://doi.org/10.1002/cncr.70620
AB  - Background: Prostate‐specific antigen (PSA) screening prevents prostate cancer death but also leads to overdiagnosis—diagnosis that would not occur during a man’s lifetime without screening—particularly in older men and those with life‐limiting comorbidities. Modern screening approaches attempt to mitigate overdiagnosis in older men by using a higher PSA threshold for further evaluation using magnetic resonance imaging (MRI), and discontinuing screening in men with low PSA levels. However, long‐term harms and benefits have not been estimated.  Methods: Two microsimulation models estimated lifetime harms and benefits of modern screening approaches in men who were screened biennially at ages 50–70 years, remained undiagnosed with prostate cancer at age 72 years, and faced varying risks of competing mortality based on previously estimated comorbidity‐adjusted life tables.  Results: By using a PSA threshold of 6.5 ng/mL for evaluation with MRI and MRI‐targeted biopsy, estimated ratios of overdiagnoses to cancer deaths prevented were similar when all men aged 70 years or older continued screening versus when only in men with PSA levels ≥ 3.0 ng/mL continued screening. For men with no comorbidities, this ratio increased from 2.7–3.1 at age 72 years to 4.5–5.1 at age 76 years. For men with severe comorbidities, this ratio increased from 9.6–10.2 at ages 72 to 11.3–12.6 at 76 years.  Conclusions: Even using modern approaches, the ratio of overdiagnoses per cancer death prevented increases with age and is at least double in men with severe life‐limiting comorbidities compared with age‐matched men with no comorbidities. The current results can help inform patients and providers about when to stop PSA screening.
SN  - 0008-543X
SN  - 1097-0142
ER  -